Guest Book

First Name:
   
Last Name:
   
Email:
   
Comments:
 
 
 
 
 
Code:

 

 Upcoming Events/New Items  Links

Marina del Rey Pompe Patient Meeting

BioMarin is currently seeking patients for a Phase 3 clinical trial in Late Onset Pompe Disease

DUKE INFANTILE ONSET POMPE PATIENT MEETING 2014

Pompe Perspectives Videos

Amicus Therapeutics Strengthens Biologics Business Strategy

MIRACLE IN MOTION

Amicus Therapeutics Announces Positive Pompe Program Updates

MEDIC ALERT PROGRAM FOR POMPE PATIENTS

March 19, 2012 Community Update for Pompe Families in the United States who Utilize Myozyme® (alglucosidase alfa) Produced at the 160 L Manufacturing Scale

Community Update for Pompe Families in the United States who Utilize Myozyme®

ADVANCE Study Fact Sheet

Amicus Therapeutics Announces First Patient in Phase 2 Study for Pompe Disease

AMICUS POMPE COMMUNITY UPDATE NEWSLETTER

Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease

Sanofi-aventis to Acquire Genzyme

BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease

POMPE IN COMMON WINTER 2010 EDITION

GENZYME: THE MAKING OF PROTEIN THERAPIES VIDEO

United States Pompe Program Update, August 9, 2010

UNITED STATES POMPE PROGRAM UPDATE, MAY 25, 2010

GENZYME RECEIVES FDA APPROVAL FOR LUMIZYME FOR POMPE DISEASE

US Pompe Program Update – December 3, 2009

POMPE PROGRAM UPDATE MAY 22, 2009

Pompe Program Update March 2, 2009

Genzyme Receives Complete Response Letter from FDA on Lumizyme Application

MYOZYME® (2000 L) SUPPLY UPDATE _US VERSION_JANUARY 2009

GUIDANCE TO THE POMPE COMMUNITY ON THE MANAGEMENT OF MYOZYME SUPPLY

GENZYME POMPE PROGRAM UPDATE NOVEMBER 17, 2008

MYOZYME PRODUCED AT THE 2000L BIOREACTOR SCALE TO RECEIVE ACCELERATED APPROVAL

Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease

Genzyme Provides Update on Myozyme® Manufacturing

Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease

REHABILITATION MANAGEMENT OF POMPE DISEASE: GREGORY T. CARTER, MD, MS

THE MYOZYME MIRACLE

FDA APPROVES GENZYMES MYOZYME® FOR ALL PATIENTS WITH POMPE DISEASE

Expensive drug gives hope to rare disease sufferer

 

MEDIC ALERT BROCHURE

MEDIC ALERT PROGRAM FOR POMPE PATIENTS

POMPE INCOMMON

New Zealand Pompe Network website

LUMIZYME HOME PAGE

HOME ADAPTIONS: SHARON KRUEGER

Canadian Association of Pompe

"WEAKLING WILLIE" BOOK

FLYING WITH A VENTILATOR IN THE USA

Association for Glycogen Storage Disease

JUAN MAGDARAOG BLOG

Myozyme Home Page

EXPRESSION OF HOPE

Amicus Therapeutics

UK Pompe Group

Helping Hands Loving Hearts

International Pompe Association IPA

Clinical Trial Information

Genzyme's Pompe Website

 
Pompe Disease | Clinical Trial Process | Donations | EP Magazine Article "Living With Pompe Disease"
Events | Guest Book | Patient Registry | Videos | Related Articles | Contact Us | Home
United Pompe 2014 All Rights Reserved.